Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,978 public trials 744 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

NCT02586493

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Ormond Beach, Florida, United States
View all 16 locations
View Trial Details
Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Sunset, Louisiana, United States
  • GSK Investigational Site Easley, South Carolina, United States
  • GSK Investigational Site Spartanburg, South Carolina, United States
  • GSK Investigational Site Union, South Carolina, United States
View all 27 locations
View Trial Details
Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01957163

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Tampa, Florida, United States
  • GSK Investigational Site New Orleans, Louisiana, United States
View all 53 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site Clearwater, Florida, United States
View all 59 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site DeLand, Florida, United States
View all 72 locations
View Trial Details
Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madisonville, Kentucky, United States
View all 50 locations
View Trial Details
Completed

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Torrance, California, United States
View all 72 locations
View Trial Details
Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01372410

Conditions
Bronchial Diseases, Bronchitis, Bronchitis, Chronic, +11 more
Locations
  • GSK Investigational Site Costa Mesa, California, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Duluth, Georgia, United States
  • GSK Investigational Site Edina, Minnesota, United States
View all 13 locations
View Trial Details
Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422

Conditions
Chronic Disease, Disease Attributes, Dyspnea, +9 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Torrance, California, United States
  • GSK Investigational Site Fort Collins, Colorado, United States
View all 27 locations
View Trial Details

Related conditions